Corbus Pharmaceuticals
CRBP
103 hedge funds and large institutions have $224M invested in Corbus Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 15 closing their positions.
36% more capital invested
Capital invested by funds: $164M → $224M (+$59.9M)
33% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 15
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
2% more funds holding
Funds holding: 101 → 103 (+2)
0.45% more ownership
Funds ownership: 1.22% → 1.67% (+0.45%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
41% less call options, than puts
Call options by funds: $2.38M | Put options by funds: $4.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$50M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$7.67M |
| 3 |
Millennium Management
New York
|
+$5.19M |
| 4 |
BlackRock
New York
|
+$1.81M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.8M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.59M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$941K |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$626K |
| 5 |
Goldman Sachs
New York
|
-$477K |
CRBP Hedge Fund Activity: Q2 2019 in Review
103 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2019, worth a combined $224M — up 36% from $164M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CRBP positions and 15 closed out — a net gain of 5 holders — while 32 added to existing stakes and 28 trimmed.
The largest buyer was ETF Managers Group, opening a new position worth an estimated $50M. The largest seller was Fidelity Investments, cutting an estimated $1.8M.
- 103 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2019, up from 101 in Q1 2019.
- Funds reported $224M of Corbus Pharmaceuticals stock for Q2 2019, up 36% quarter-over-quarter.
- 20 funds opened new Corbus Pharmaceuticals positions in Q2 2019 and 15 closed out, a net change of +5 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2019 was ETF Managers Group, an estimated $50M added.
- The largest Corbus Pharmaceuticals seller in Q2 2019 was Fidelity Investments, an estimated $1.8M sold.
Based on aggregated 13F filings for Q2 2019.